CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- 4 Shares withheld for taxes CFO gave up 2,129 shares (to pay taxes)
- 4 Grant or award Director acquired 5,054 shares (grant or award)
- 4 Grant or award Director acquired 5,054 shares (grant or award)
- 4 Grant or award Director acquired 5,054 shares (grant or award)
- 4 Grant or award Director acquired 5,054 shares (grant or award)
- 4 Grant or award Director acquired 5,054 shares (grant or award)
- 4 Grant or award Director acquired 5,054 shares (grant or award)
- 4 Planned sale Director sold 4,938 shares at an average $39.74 ($196,230)
- 4 Planned sale Director sold 5,112 shares at an average $39.74 ($203,152)
- 4 Shares withheld for taxes Director gave up 5,133 shares (to pay taxes)
- 4 Shares withheld for taxes Director gave up 2,378 shares (to pay taxes)
- 4 Shares withheld for taxes Director gave up 2,179 shares (to pay taxes)
- 4 Shares withheld for taxes Director gave up 1,743 shares (to pay taxes)
- 4 Shares withheld for taxes Director gave up 2,905 shares (to pay taxes)
- 4 Planned sale Director sold 20,000 shares at $39.90 ($798,000)
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at an average $35.77 ($7,153,393)
- 4 Shares withheld for taxes CFO gave up 5,749 shares (to pay taxes)
- 4 Shares withheld for taxes President & Immunovant CEO gave up 13,909 shares (to pay taxes)
- 4 Open-market sale President & CIO sold 335,174 shares at an average $36.88 ($12,360,813)
- 4 Open-market sale President & CIO sold 664,826 shares at an average $36.34 ($24,160,402)
Page 2 of 26 · 511 filings